Results 21 to 30 of about 151,327 (305)

Treatment options for PNET liver metastases. a systematic review [PDF]

, 2018
Pancreatic neuroendocrine tumors (PNETs) are rare pancreatic neoplasms. About 40-80% of patients with PNET are metastatic at presentation, usually involving the liver (40-93%). Liver metastasis represents the most significant prognostic factor.
Aurello, Paolo, Crovetto, Anna, Debs, Tarek, Mangogna, Livia Maria, Moschetta, Giovanni, Nigri, Giuseppe, Persechino, Raffaello, Petrucciani, Niccolò, Ramacciato, Giovanni   +8 more
core   +1 more source

Pancreatic neuroendocrine tumors

Intractable & Rare Diseases Research, 2017
Pancreatic neuroendocrine neoplasms (pNENs) are a heterogeneous group of tumors including well differentiated pancreatic neuroendocrine tumors (pNETs) and neuroendocrine carcinomas (pNECs). The incidence of pNENs has increased over the past few decades.
Varas-Lorenzo, Modesto J., Cugat-Andorra, Esteban, Capdevila-Castillón, Jaume   +2 more
openaire   +7 more sources

The Interplay of Four Main Pathways Recomposes Immune Landscape in Primary and Metastatic Gastroenteropancreatic Neuroendocrine Tumors

Frontiers in Oncology, 2022
BackgroundThe four major pathways in gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) including chromatin remodeling, DNA damage repair, activation of mTOR signaling, and telomere maintenance were mediated by some critical molecules and ...
Xin Lou, Xin Lou, Xin Lou, Xin Lou, Xin Lou, Heli Gao, Heli Gao, Heli Gao, Heli Gao, Heli Gao, Xiaowu Xu, Xiaowu Xu, Xiaowu Xu, Xiaowu Xu, Xiaowu Xu, Zeng Ye, Zeng Ye, Zeng Ye, Zeng Ye, Zeng Ye, Wuhu Zhang, Wuhu Zhang, Wuhu Zhang, Wuhu Zhang, Wuhu Zhang, Fei Wang, Fei Wang, Fei Wang, Fei Wang, Fei Wang, Jie Chen, Jie Chen, Jie Chen, Jie Chen, Jie Chen, Yue Zhang, Xuemin Chen, Yi Qin, Yi Qin, Yi Qin, Yi Qin, Yi Qin, Xianjun Yu, Xianjun Yu, Xianjun Yu, Xianjun Yu, Xianjun Yu, Shunrong Ji, Shunrong Ji, Shunrong Ji, Shunrong Ji, Shunrong Ji   +51 more
doaj   +1 more source

Tumor size and perineural invasion predict outcome of gastric high-grade neuroendocrine neoplasms

Endocrine Connections, 2021
A new subcategory, grade 3 neuroendocrine tumors, is incorporated into the grading system of pancreatic neuroendocrine neoplasms in the 2017 WHO c lassification in order to differentiate grade 3 neuroendocrine tumors from neuroendocri ne carcinomas.
Qi Zhang, Hongshan Wang, Yanhong Xie, Suming Huang, Ke Chen, Botian Ye, Yupeng Yang, Jie Sun, Hongyong He, Fenglin Liu, Zhenbin Shen, Weidong Chen, Kuntang Shen, Yuan Ji, Yihong Sun   +14 more
doaj   +1 more source

The novel mTOR inhibitor RAD001 (Everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells [PDF]

, 2007
Background/Aim: Tumors exhibiting constitutively activated PI(3) K/Akt/mTOR signaling are hypersensitive to mTOR inhibitors such as RAD001 (everolimus) which is presently being investigated in clinical phase II trials in various tumor entities, including
Albert JM, Auernhammer CJ, Boulay A, Boulay A, Bousquet C, Burkhard Göke, Cao C, Christoph J. Auernhammer, Enrico N. De Toni, Faivre S, Gerald Spöttl, Grewe M, Heinrich H.D. Meyer, Hosoi H, Jeng YJ, Jennifer Meinecke, Kathrin Zitzmann, Kawamata S, Kirchner GI, Luo J, O?Reilly KE, Oberg K, Ramage JK, Sawyers CL, Shah T, Shaw RJ, Stephan Brand, Sun SY, Vignot S, von Wichert G, Wang L, Wanner K, Wendel HG, Wullschleger S, Yao JC, Yee KW   +35 more
core   +1 more source

Neuroendocrine Tumor Markers

Frontiers in Neuroendocrinology, 2001
Tumor markers used in the diagnosis and follow-up of patients with neuroendocrine tumors are in most instances not specific for a given tumor and circulate under normal conditions in the serum, making their use as an early diagnostic tool difficult (low sensitivity).
Lamberts, S.W.J., Hofland, Leo, Nobels, FRE   +2 more
openaire   +2 more sources

MEN1 promotes ferroptosis by inhibiting mTOR-SCD1 axis in pancreatic neuroendocrine tumors

Acta Biochimica et Biophysica Sinica, 2022
Pancreatic neuroendocrine tumor (pNET) is the second most common malignant tumors of the pancreas. Multiple endocrine neoplasia 1 ( MEN1) is the most frequently mutated gene in pNETs and MEN1-encoded protein, menin, is a scaffold ...
Ye Zeng, Chen Haidi, Ji Shunrong, Hu Yuheng, Lou Xin, Zhang Wuhu, Jing Desheng, Fan Guixiong, Zhang Yue, Chen Xuemin, Zhuo Qifeng, Chen Jie, Xu Xiaowu, Yu Xianjun, Xu Jin, Qin Yi, Gao Heli   +16 more
doaj   +1 more source

Clinical study of robot and laparoscopic minimally invasive surgery for well-differentiated pancreatic neuroendocrine tumors [PDF]

Zhongguo aizheng zazhi, 2022
Background and purpose: Pancreatic neuroendocrine tumor (pNET) is a rare tumor. At present, there is still a lack of large-scale clinical research data to summarize the clinical effect of minimally invasive technology in the treatment of pNET. This study
LIU Wensheng, JI Shunrong, ZHUO Qifeng, GAO Heli, SHI Yihua, XU Wenyan, LIU Mengqi, LI Zheng, YU Xianjun, CHEN Jie, XU Xiaowu
doaj   +1 more source

Prediction of progression-free survival in patients with advanced, well-differentiated, neuroendocrine tumors being treated with a somatostatin analog: the GETNE-TRASGU study [PDF]

, 2019
Artículo escrito por un elevado número de autores, sólo se referencian el que aparece en primer lugar, y los autores pertenecientes a la UAMSomatostatin analogs (SSAs) are recommended for the first-line treatment of most patients with well ...
Carmona Bayonas, Alberto, Marazuela, Mónica   +1 more
core   +1 more source

Discussing motherhood when the oncological prognosis is dire: ethical considerations for physicians

ESMO Open, 2020
Physicians are increasingly open to discussing and supporting pregnancy after cancer treatment. However, counselling patients who are seeking pregnancy despite advanced oncological disease and/or uncertain prognosis is still challenging. Two paradigmatic
Francesca Spada, Alma Linkeviciute, Nicola Fazio, Fedro A Peccatori   +3 more
doaj   +1 more source